2022-000753-80: Clinical research study to learn about the effect and safety of different doses of FE 999302 when given as a single dose for final development of the eggs after ovarian stimulation Estudio de investigación clínica para conocer el efecto y la seguridad de diferentes dosis de FE 999302 cuando se administra como dosis única para el desarrollo final de los óvulos después de la estimulación ovárica |
|
|
| Ongoing | 2 | 500 | Europe | NOVAREL, OVITRELLE, FE 999302, FE 999086, Solution for injection, Powder and solvent for solution for injection, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, NOVAREL, OVITRELLE | Ferring Pharmaceuticals A/S, Ferring Pharmaceuticals A(S | Infertility Infertilidad, Infertility Infertilidad, Body processes [G] - Reproductive physiologi cal processes [G08] | | | | |
CS-EOSP-ICSI, NCT04071574: Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility |
|
|
| Completed | 1/2 | 200 | RoW | Human Chorionic Gonadotropin (hCG), OVITRELLE / PREGNYL, Gonadotropins, MENOPUR, GNRH-A Triptorelin, DECAPEPTYL, GnRH antagonist, CETROTIDE / ORGULATRON | Lebanese University | Female Infertility, Female Infertility Due to Ovulatory Disorder, Premature Ovarian Failure, Polycystic Ovary Syndrome, Female Infertility of Tubal Origin, Ectopic Pregnancy, Salpingitis, Female Infertility Due to Tubal Block, Female Infertility Due to Tubal Occlusion, Hydrosalpinx, Female Infertility - Cervical/Vaginal, Female Infertility Endocrine, Endometriosis, Fibroids, Congenital Uterine Anomaly, Infections Uterine, Female Infertility of Other Origin | 08/19 | 05/23 | | |
